Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | EP300 | Q09472 | 2/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.30 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
| ▸ | C1S | P09871 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575940 | 0.86 | PLAT (0.42) | PLATMEN1POLBKMT2AGABRA1 | |
| SCHEMBL13031213 | 0.80 | PLAT (0.32) | PLATMEN1POLBKMT2AGABRA1 | |
| SCHEMBL3583375 | 0.79 | GABRA1 (0.43) | PLATGABRA1GABRG2GABRB3EP300 | |
| SCHEMBL3588524 | 0.79 | HTR2C (0.44) | PLATMEN1POLBKMT2AMAP3K12 | |
| SCHEMBL3588162 | 0.74 | PTGS1 (0.41) | PLAT | |
| SCHEMBL3576329 | 0.73 | MEN1 (0.57) | PLATMEN1POLBKMT2ATLR7 | |
| SCHEMBL3634136 | 0.72 | TRPC3 (0.34) | MEN1KMT2A | |
| SCHEMBL3580316 | 0.72 | PTGS2 (0.43) | PLATMEN1KMT2AGABRA1GABRG2 | |
| SCHEMBL3579884 | 0.72 | MAPT (0.41) | — | |
| SCHEMBL3581758 | 0.72 | SHMT1 (0.32) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | PLAT 2714/4885MEN1 4848/4885POLB 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.